Form 4: Clene Inc. CFO Granted Stock Options

Clene Inc.'s Chief Financial Officer, Morgan R. Brown, was granted stock options for 1,000,000 shares of common stock on June 7, 2024.

Summary

• Morgan R. Brown, the Chief Financial Officer of Clene Inc., was granted stock options on June 7, 2024.
• The options are for a total of 1,000,000 shares of Clene Inc. common stock.
• The exercise price for the options is $0.37 per share.
• 400,000 of the options vest starting June 7, 2025, with 25% vesting initially and the remainder vesting in 36 equal monthly installments.
• 600,000 of the options vest based on specific milestones: 33.3% upon FDA acceptance of a New Drug Application (NDA), 33.3% upon FDA approval of an NDA, and 33.4% upon achieving $100,000,000 in revenues from approved drug sales.
• The options expire on June 6, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting confidence in the company's future prospects and alignment of management incentives. The vesting conditions tied to FDA approvals and revenue targets are positive indicators.

Positives

• The stock option grant aligns the CFO's interests with the company's success, particularly regarding drug development and revenue generation.
• The vesting schedule for a portion of the options is tied to achieving significant milestones, such as FDA acceptance and approval of an NDA, and reaching $100 million in revenue, which could incentivize performance.

Risks

• The vesting of a significant portion of the options is contingent on achieving specific milestones related to drug development and sales, which may not be realized.
• If the company does not receive FDA acceptance or approval for its NDA or fails to achieve the revenue target, the CFO may not fully vest in all of the granted options.

Future Outlook

The vesting of the options is tied to future regulatory and financial milestones, indicating the company's focus on drug development and commercialization.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with the company's long-term success, particularly in achieving regulatory approvals and revenue targets.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules tied to regulatory milestones (FDA approval) and revenue targets are also common, aligning executive incentives with company performance.
• Comparable companies in the biotech sector, such as Biohaven Pharmaceuticals or Amylyx Pharmaceuticals, often utilize similar stock option plans to incentivize their leadership teams.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the CFO's interests with the company's success.
• Employees may be motivated by the potential for the company to achieve its milestones and increase shareholder value.
• The vesting conditions tied to FDA approvals and revenue targets could impact the company's relationships with regulatory agencies and potential customers.

Key Dates